时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
研究问题
In the adjuvant setting, concurrent cisplatin may be unsuitable for patients unable to tolerate platinum-based therapy or with cisplatin-specific contraindications, including clinically significant renal impairment, hearing loss, peripheral neuropathy, or poor performance status (4, 5).For a patient whose tumor is anatomically resectable but whose physiological reserve is inadequate, the immediate objective may be to restore fitness for definitive treatment.；The intended goal was to enable a less extensive and less morbid operation, including a reduced reconstructive burden, while retaining complete tumor resection as the oncological objective.2.3Therapeutic interventionTreatment began on 16 October 2025.；Detailed postoperative morbidity and objective functional outcomes are not fully described.
方法
In older patients, these problems may coexist with substantial functional vulnerability (2).；In the adjuvant setting, concurrent cisplatin may be unsuitable for patients unable to tolerate platinum-based therapy or with cisplatin-specific contraindications, including clinically significant renal impairment, hearing loss, peripheral neuropathy, or poor performance status (4, 5).For a patient whose tumor is anatomically resectable but whose physiological reserve is inadequate, the immediate objective may be to restore fitness for definitive treatment.；Surgery was completed in approximately 88% of participants in each group (7).
核心结论
It does not imply that systemic therapy replaces resection or that tumor regression alone justifies less extensive surgery.Neoadjuvant and perioperative programmed cell death protein 1 (PD-1) blockade have demonstrated clinical activity in resectable head and neck squamous cell carcinoma (HNSCC), including improved event-free survival with perioperative pembrolizumab added to standard care in KEYNOTE-689 (6, 7).；These findings support further investigation of this combination but do not establish its efficacy or perioperative safety in frail surgical candidates.；Panel D demonstrates PD-L1 staining with prominent brown labeling, especially at the periphery.
局限
The clinical context included rapid weight loss, reduced oral intake, functional limitation, and cardiovascular comorbidities.；Rising albumin and prealbumin should not, however, be treated as independent proof that malnutrition or muscle depletion resolved: these proteins are influenced by inflammation and are not stand-alone measures of nutritional status (13).；A matched cohort reported by Tang et al. found no increase in most evaluated postoperative adverse events after neoadjuvant pembrolizumab in oral cavity cancer, but this does not establish the safety of a different combination in a patient presenting with ECOG performance status 3 (14).The rationale for dual PD-1/EGFR targeting requires similar caution.
对本项目的价值
中等价值：属「衰老机制与老年临床」方向；其他衰老相关栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.6/5（★★★☆☆）
全文来源
PubMed PMC JATS（正文 26,537 字符，题名指纹 1.0，已过 PubMed PMCID 官方关联 + 题名指纹 + 正文长度归属校验）
原文题录
- 中文题名：新辅助帕博利珠单抗联合尼妥珠单抗作为桥梁治疗衰弱老年上颌牙龈与腭部鳞癌患者：病例报告
- 英文标题：Neoadjuvant pembrolizumab plus nimotuzumab as a bridge to surgery in a frail elderly patient with maxillary gingival and palatal squamous cell carcinoma: a case report.
- 期刊与标识：Frontiers in oncology · PMID 42973506 · DOI 10.3389/fonc.2026.1993693 · PMC PMC13724471